BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...

CHARLOTTESVILLE, Va. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cavion, Inc., a clinical stage biotechnology company developing novel therapeutics for neurological diseases, announced today that their first ...

Bright Minds Biosciences Inc. (DRUG) has been able to initiate its phase 2 BREAKTHROUGH study using its 5-HT2C agonist BMB-101 for the treatment of adult patients with classic Absence Epilepsy and ...

New contributions to the field of epilepsy have opened a window into the cellular events that occur in the brain during absence seizures. At first, the teacher described her six-year-old student as ...

The electroencephalogram (EEG) provides important information to aid clinicians in the diagnosis of epilepsy. However, EEG techniques are associated with certain limitations, as discussed in the ...

This transcript has been edited for clarity. Andrew N. Wilner, MD: Welcome to Medscape. I'm your host, Dr Andrew Wilner, reporting on the annual American Epilepsy Society meeting. With me today is my ...

“Do you know why you shouldn’t talk to strangers?” asks a police officer standing at the front of a classroom to a room full of students. Emily’s hand shoots up and the teacher encourages her to ...

Epileptic seizures used to rule Cheryl Castle's life, striking up to 42 times in three hours and leaving the once-active mother of three essentially housebound. But a new device recently implanted in ...